Sei Investments Co. Purchases 24,723 Shares of Biohaven Ltd. (NYSE:BHVN)

Sei Investments Co. raised its stake in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 55.7% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 69,082 shares of the company's stock after purchasing an additional 24,723 shares during the period. Sei Investments Co. owned 0.07% of Biohaven worth $2,580,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. American Century Companies Inc. raised its position in shares of Biohaven by 9.5% during the 4th quarter. American Century Companies Inc. now owns 558,761 shares of the company's stock valued at $20,870,000 after purchasing an additional 48,286 shares during the period. Quantbot Technologies LP purchased a new stake in Biohaven in the 4th quarter worth $355,000. DCF Advisers LLC raised its holdings in Biohaven by 16.1% during the fourth quarter. DCF Advisers LLC now owns 36,000 shares of the company's stock valued at $1,345,000 after acquiring an additional 5,000 shares during the period. Magnetar Financial LLC lifted its position in shares of Biohaven by 498.7% in the fourth quarter. Magnetar Financial LLC now owns 39,260 shares of the company's stock valued at $1,466,000 after acquiring an additional 32,702 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in shares of Biohaven by 31.6% in the fourth quarter. Teacher Retirement System of Texas now owns 23,320 shares of the company's stock worth $871,000 after acquiring an additional 5,600 shares during the period. Hedge funds and other institutional investors own 88.78% of the company's stock.

Analyst Ratings Changes

A number of research firms recently commented on BHVN. JPMorgan Chase & Co. lowered their price target on Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a report on Wednesday, March 5th. Cantor Fitzgerald reissued an "overweight" rating on shares of Biohaven in a report on Tuesday, December 17th. HC Wainwright restated a "buy" rating and set a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 price target on shares of Biohaven in a report on Tuesday, March 4th. Finally, Morgan Stanley dropped their price objective on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a report on Friday, March 7th. Fourteen analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $62.77.

Remove Ads

Insiders Place Their Bets

In other Biohaven news, Director John W. Childs bought 32,700 shares of the firm's stock in a transaction dated Tuesday, March 4th. The stock was acquired at an average cost of $30.47 per share, for a total transaction of $996,369.00. Following the completion of the transaction, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.00% of the stock is owned by insiders.

Biohaven Trading Up 12.8 %

NYSE:BHVN traded up $2.11 during midday trading on Wednesday, hitting $18.65. 2,600,330 shares of the company traded hands, compared to its average volume of 1,116,257. The firm has a market capitalization of $1.90 billion, a P/E ratio of -1.99 and a beta of 1.33. The firm's fifty day moving average is $31.30 and its 200-day moving average is $39.99. Biohaven Ltd. has a 12-month low of $15.82 and a 12-month high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last announced its earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, research analysts expect that Biohaven Ltd. will post -8.9 EPS for the current fiscal year.

Biohaven Company Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.